TY - JOUR
KW - Costs
KW - Healthcare resource use
KW - Organ damage
KW - Systemic lupus erythematosus
AU - H. Stirnadel-Farrant
AU - S. Golam
AU - B. Naisbett-Groet
AU - D. Gibson
AU - J. Langham
AU - S. Langham
AU - M. Samnaliev
AD - BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK. Heide.Stirnadel-Farrant@astrazeneca.com.
Oncology Business Unit, AstraZeneca, AstraZeneca Academy House, 136 Hills Road, Cambridge, CB2 8PA, UK. Heide.Stirnadel-Farrant@astrazeneca.com.
BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden.
BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK.
Health Economics, AstraZeneca, Cambridge, UK.
Epidemiology Group, Maverex Limited, Newcastle-Upon-Tyne, UK.
Health Economics Group, Maverex Limited, Newcastle-Upon-Tyne, UK.
Statistical Group, Maverex Limited, Newcastle-Upon-Tyne, UK.
AN - 37400683
BT - Rheumatol Ther
DO - 10.1007/s40744-023-00567-9
DP - NLM
ET - 2023/07/04
LA - eng
N1 - Stirnadel-Farrant, Heide A
Golam, Sarowar M
Naisbett-Groet, Barbara
Gibson, Danny
Langham, Julia
Langham, Sue
Samnaliev, Mihail
Journal Article
England
Rheumatol Ther. 2023 Jul 3. doi: 10.1007/s40744-023-00567-9.
PY - 2023
SN - 2198-6576 (Print)
2198-6576
T2 - Rheumatol Ther
TI - Healthcare Resource Use and Costs Associated with Organ Damage in Newly Diagnosed Adults with Systemic Lupus Erythematosus in the UK
ER -